Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease

Atherosclerosis

Volumn 210, Issue 2, 2010, Pages 619-624

  Urbonaviciene, Grazina ^a   Frystyk, Jan ^b   Flyvbjerg, Allan ^b   Henneberg, Eskild W ^a   Lindholt, Jes S ^a  

^a VIBORG HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adiponectin; Cardiovascular event; Mortality; Peripheral artery disease

Indexed keywords

ADIPONECTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGE; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; DIABETES MELLITUS; DRUG USE; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNOASSAY; LEG ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; STATISTICAL SIGNIFICANCE;

ADIPONECTIN; AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK;

EID: 77953231744     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.12.030     Document Type: Article

References (36)

1. Mazzone T. Adipose tissue and the vessel wall. Curr Drug Targets 2007, 8(November (11)):1190-1195.
2. Giannessi D., Maltinti M., Del R.S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 2007, 56(December (6)):459-467.
3. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26(May (3)):439-451.
4. Trujillo M.E., Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005, 257(February (2)):167-175.
5. Hug C., Lodish H.F. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol 2005, 5(April (2)):129-134.
6. Lindsay R.S., Resnick H.E., Zhu J., et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005, 25(March (3)):e15-e16.
7. Maahs D.M., Ogden L.G., Kinney G.L., et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111(February (6)):747-753.
8. Iwashima Y., Horio T., Suzuki Y., et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 2006, 188(October (2)):384-390.
9. Fortuno A., Rodriguez A., Gomez-Ambrosi J., Fruhbeck G., Diez J. Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. J Physiol Biochem 2003, 59(March (1)):51-60.
10. Frystyk J., Tarnow L., Hansen T.K., Parving H.H., Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005, 48(September (9)):1911-1918.
11. Efstathiou S.P., Tsioulos D.I., Tsiakou A.G., et al. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 2005, 36(September (9)):1915-1919.
12. Kanaya A.M., Wassel F.C., Vittinghoff E., et al. Serum adiponectin and coronary heart disease risk in older Black and White Americans. J Clin Endocrinol Metab 2006, 91(December (12)):5044-5050.
13. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112(September (12)):1756-1762.
14. Hashimoto N., Kanda J., Nakamura T., et al. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism 2006, 55(December (12)):1653-1657.
15. Pilz S., Mangge H., Wellnitz B., et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006, 91(November (11)):4277-4286.
16. Hajer G.R., van der G.Y., Olijhoek J.K., Edlinger M., Visseren F.L. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J 2007, 154(October (4)):750-757.
17. George J., Patal S., Wexler D., et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006, 92(October (10)):1420-1424.
18. Laughlin G.A., Barrett-Connor E., May S., Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007, 165(January (2)):164-174.
19. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002, 13(January (1)):134-141.
20. Combs T.P., Berg A.H., Rajala M.W., et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003, 52(February (2)):268-276.
21. Nishizawa H., Shimomura I., Kishida K., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002, 51(September (9)):2734-2741.
22. Andersen K.K., Frystyk J., Wolthers O.D., Heuck C., Flyvbjerg A. Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab 2007, 92(May (5)):1857-1862.
23. Bottner A., Kratzsch J., Muller G., et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004, 89(August (8)):4053-4061.
24. Laughlin G.A., Barrett-Connor E., May S. Sex-specific determinants of serum adiponectin in older adults: the role of endogenous sex hormones. Int J Obes (Lond) 2007, 31(March (3)):457-465.
25. Wannamethee S.G., Tchernova J., Whincup P., et al. Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronary heart disease risk-related parameters. Int J Obes (Lond) 2007, 31(July (7)):1089-1098.
26. Golledge J., Leicht A., Crowther R.G., et al. Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication. J Vasc Surg 2007, 45(January (1)):40-46.
27. Frystyk J., Berne C., Berglund L., et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007, 92(February (2)):571-576.
28. Dieplinger B., Poelz W., Haltmayer M., Mueller T. Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease. Clin Chem Lab Med 2006, 44(7):830-833.
29. Dieplinger B., Poelz W., Haltmayer M., Mueller T. Association of adiponectin and amino terminal proBNP in peripheral arterial disease. Clin Chim Acta 2007, 377(February (1-2)):192-197.
30. Lim P.S., Hu C.Y., Wu M.Y., Wu T.K., Chang H.C. Plasma adiponectin is associated with ankle-brachial index in patients on haemodialysis. Nephrology (Carlton) 2007, 12(December (6)):546-552.
31. Schnabel R., Messow C.M., Lubos E., et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J 2008, 29(March (5)):649-657.
32. Dekker J.M., Funahashi T., Nijpels G., et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008, (January 22).
33. Wannamethee S.G., Shaper A.G., Lennon L. Reasons for intentional weight loss, unintentional weight loss, and mortality in older men. Arch Intern Med 2005, 165(May (9)):1035-1040.
34. Maiolino G., Cesari M., Sticchi D., et al. Plasma adiponectin for prediction of cardiovascular events and mortality in high-risk patients. J Clin Endocrinol Metab 2008, 93(September (9)):3333-3340.
35. von E.M., Hamann A., Twardella D., et al. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J 2008, 29(May (10)):1307-1315.
36. Rathmann W., Herder C. Adiponectin and cardiovascular mortality: evidence for " reverse epidemiology" Horm Metab Res 2007, 39(January (1)):1-2.